Vol. 17/No. 9

Riccardo Dalla-Favera, MD, whose work has helped characterize the molecular drivers of B-cell lymphomas, was honored in the Lymphoma category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

The new generation of drugs that have emerged as part of antiemetic cocktails have demonstrated greater success in preventing and controlling CINV but the symptoms still present significant obstacles in anticancer therapy.

Rudolph M. Navari, MD, PhD, discusses the evolving landscape of antiemetic therapy.

Although precision oncology has promise, its success hinges on the availability of clinical trials of targeted therapies.

Raju Kucherlapati, PhD, serves as principal investigator of a Genome Characterization Center as part of The Cancer Genome Atlas program, a National Cancer Institute initiative aimed at defining the copy number changes and structural aberrations present in many different cancer types.

Intraperitoneal therapy was not superior to intravenous treatment when used in combination with bevacizumab (Avastin) as a regimen for patients with advanced ovarian cancer.

Treatment options for patients with squamous non–small cell lung cancer are expanding rapidly yet the field is still lagging in targeted therapies and curative strategies

Patients with relapsed chronic lymphocytic leukemia face a difficult treatment journey, but a phase III safety and efficacy trial involving the second-generation Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) will help inform oncologists about whether the emerging agent can offer a greater benefit to patients with high-risk disease over ibrutinib (Imbruvica).

A collaborative patient reported outcome-based care approach resulted in better outpatient symptom management and a decrease in end-of-life hospitalizations and costs for late-stage cancer patients.

Clinical oncologists may not be fully aware of shortcomings in the laboratory research paradigm that have the potential to distort the scientific underpinnings of vital cancer studies.

The cascade of news about cancer research—whether it’s about a new drug, biomarker, or treatment approach—has become an ever-present feature of the oncology landscape